CD39,CD103和PD-1可作为各种癌症中肿瘤反应性CD8+TIL的标志物。高级别浆液性卵巢癌(HGSC)需要更有效的免疫治疗,评估TIL在HGSC中表达这些标志物的各种组合的表型和预后意义。 方法:通过流式细胞术、单细胞测序和化疗前/化疗后HGSC标本的多色免疫荧光评估CD39、CD103、PD-1和其他免疫标志物的表达。 结论:CD39、...
DP细胞与DN细胞的基因表达差异也可以看出CD8细胞中DP细胞高表达耗竭基因(HAVCR2,LAYN,TIGIT,PDCD1,CTLA4),细胞毒性标志物(GZMA,GZMB,PRF1,NKG7)和增殖相关基因MCM。 总之,具有细胞毒性,耗竭和增殖表型的DP细胞在高IRScore组中富集。 6. CD45+CD3+CD103+CD39+可预测结直肠癌预后和对ICB治疗的反应 计算CD45+CD...
另有研究建立了111例接受单药抗PD-(L)1单抗治疗的晚期NSCLC患者的回顾性队列(图1)。将患者按肿瘤CD103+CD8+细胞浸润进行分层时,发现具有CD103+CD8+细胞高浸润的肿瘤患者的iPFS显著增加,中位iPFS达到30个月(95% CI 2.73 -未达到)(Corgnac et al., 202...
由图 5 可知,CD61+ TILs 不但未出现效应反应的衰退现象,反而呈现出免疫效应表型增强的态势。值得关注的是,相较于 CD61 - TILs,CD61+ TILs 的 PD - 1 表达量有所上升,而 Tim - 3 与 TIGIT 的表达量则有所降低。这一现象可通过 CD61+ TILs 中 PD - 1+Tim - 3+TIGIT + 共表达频率较低得以证实。
Provided herein are TILs that are in CD39, CD103 and/or both. In some embodiments, the subject TILs are produced by genetically manipulating a population of TILs that have been selected for expression of (i) PD-1, (ii) CD39, (iii) CD103, (iv) the combination of (i) and (ii), ...
Using quantitative multiplex immunofluorescence on cohorts of non-small cell lung cancer patients treated with anti-PD-(L)1, we show that an increased density of CD103+CD8+ lymphocytes in immunotherapy-naive tumors is associated with greatly improved outcomes. The density of CD103+CD8+ cells ...
Besides GM-CSF, RA and TLR2 signalling, also b-catenin-dependent signals, uptake of apoptotic DCs and PD-1 ligation may imprint Foxp3 þ Treg induction (reviewed in ref. 21). In contrast, it is much less clear which signals abrogate Treg induction by DCs, for example in situations ...
为了明确TIL亚群对高级别浆液性卵巢癌 (HGSC)的预后影响,该研究通过高维流式细胞术、单细胞测序和多重荧光免疫组化技术(mIHC)评估了CD8+ TIL和CD4+ TIL共表达CD39、CD103 …
Programmed death ligand-1 (PD-L1) was broadly expressed by leukocytes, and PD-1 was expressed by T lymphocytes; however, αPD-1 treatment had no effect on tumor growth alone or in combination with paclitaxel (PTX) (Figure S1A), consistent with previous findings in combination with ...
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–8. 5. Cheon IS, Son YM, Sun J. Tissue-resident memory T cells and lung immunopa- thology. Immunol Rev. 2023;316:63–83. 6. Chen L, Shen Z. Tissue-resident memory T cells and ...